title: Maintenance therapy involving a tapering dose of danazol or mid/low doses of oral contraceptive after gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain.
abstract: Pelvic pain associated with endometriosis was treated by the long-term administration of a tapering dose of danazol or mid/low doses of oral contraceptives after the end of therapy involving a GnRH agonist (GnRH-a). Results demonstrated that each of these three therapies is a practical and efficient treatment regimen to maintain the relief of pelvic pain achieved by GnRH-a therapy, at least for a period of 12 months.
authors.affiliation: Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan. kitawaki@koto.kpu-m.ac.jp
authors.forename: Jo
authors.initials: J
authors.lastname: Kitawaki
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ishihara
authors.forename: Miyo
authors.initials: M
authors.lastname: Kiyomizu
authors.forename: Hideo
authors.initials: H
authors.lastname: Honjo
mesh_terms: D018394:CA-125 Antigen / Q000097:blood; D003276:Contraceptives, Oral / Q000627:therapeutic use*; D003613:Danazol / Q000627:therapeutic use*; D004412:Dysmenorrhea / Q000517:prevention & control; D004715:Endometriosis / Q000150:complications* / Q000473:pathology; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D017699:Pelvic Pain / Q000188:drug therapy* / Q000209:etiology
chemical_list: D018394:CA-125 Antigen; D003276:Contraceptives, Oral; D004965:Estrogen Antagonists; D007987:Gonadotropin-Releasing Hormone; D003613:Danazol